...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

Trod Medical Receives US Patent Allowance for Prostate Focal Therapy Encage™ Device

| Print |
Wednesday, 08 February 2017 10:00 (UTC + 1)

TROD medical logo

Leuven, Belgium, February 08, 2017 / B3C newswire / -- Trod Medical NV, the medical device company with FDA-cleared and CE Marked products for focal ablation, announces the issuance of a new patent allowance by the United States Patent and Trademark Office (USPTO), entitled  “Method of percutaneous localized or focal treatment of prostate lesions using radio frequency”, with patent ID US 20110288541 A1.

The patent covers a surgical technique for application with Trod Medical’s Encage™ radio frequency ablation device used in Prostate Focal Therapy. The patent is part of a family of patents, including one for a “Method to remove a tumor using a percutaneous surgical instrument“, with patent ID US 9445866 B2, announced in August 2016.

“This new patent adds an additional layer of protection, extending beyond families of patents we have covering Encage’s original design, including robotic handling, and guiding systems”, said Andre Faure, CEO of Trod Medical. He continued, “Our strong family of patents, combined with Encage’s superior clinical outcomes for men with prostate cancer, puts Trod Medical in a dominant position in this very significant and growing market”.

TROD Medical’s Encage is a bipolar, radio frequency-based, helical ablation probe enabling minimally invasive focused soft tissue ablation.


About TROD Medical NV
TROD Medical is a medical device company, focused on the development of tools for use in the focal ablation of soft tissues. The Company, founded in 2006 by Dr. Andre Faure, has developed significant expertise in developing innovative ablation technologies, particularly radio frequency (RF) ablation devices.

Trod Medical’s proprietary product, Encage, is a bipolar, radio frequency-based, helical ablation probe enabling minimally invasive focused soft tissue ablation. The device represents a major breakthrough in treatments where collateral tissue damage is a significant burden to patients, such as those with prostate cancer.

TROD Medical is a private venture-backed company with headquarters in Leuven (Belgium) and facilities in the Tampa Bay area (USA), and Paris (France).


Contacts

TROD Medical
Andre Faure, CEO
This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Instinctif Partners
Daniel Gooch/Dr Christelle Kerouedan
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
+44 (0)20  7866 7905